Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$150.30 USD

150.30
680,430

+0.34 (0.23%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (53 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Accuray's (ARAY) New Offering to Boost Radiation Treatment Plans

Accuray's (ARAY) latest offering is likely to improve radiation treatment.

Should Value Investors Buy Quest Diagnostics (DGX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

Investors are optimistic about Zimmer Biomet (ZBH) on business recovery and expansion in emerging markets.

Veradigm's (MDRX) New Tie-Up to Boost Patients' Health Outcomes

Veradigm's (MDRX) latest partnership is likely to promote value-based care initiatives for healthcare providers and the patients they serve.

Shaun Pruitt headshot

Top Medical Stocks to Buy Amid Market Volatility

While there is no guarantee that medical stocks will offer a hedge against market volatility, healthcare is essential even during economic uncertainty.

Here's Why You Should Retain Ecolab (ECL) Stock for Now

Ecolab's (ECL) strength in its business raises optimism about the stock.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

Investors are optimistic about Medtronic (MDT) on strong global expansion.

Derek Lewis headshot

Buy These 3 Low-Beta Stocks to Navigate Volatility

Adding low-beta stocks can be a great way to counter volatility, as these stocks are less sensitive to the market's overall movements

3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio

Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.

Here's Why You Should Invest in Penumbra (PEN) Stock for Now

Investors are optimistic about Penumbra (PEN), driven by growth in vascular and neuro businesses.

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now

Investors are optimistic about Omnicell (OMCL), led by its digital transformation strategy.

Here's Why You Should Retain Inspire Medical (INSP) Stock Now

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

NextGen (NXGN) Extends Agreement to Boost Athletico's Footprint

NextGen's (NXGN) latest extended agreement is likely to reflect its solutions' potential to aid healthcare organizations at all stages of growth.

Here's Why Investors Should Invest in Abbott (ABT) Stock Now

Investors are optimistic about Abbott (ABT) on strong growth in the Diagnostics business and upbeat guidance.

QIAGEN (QGEN) Extends QIAwave Product Line With New Kit

QIAGEN's (QGEN) new QIAwave kits broaden its selection of environmentally friendly products and reaffirm its commitment to helping researchers advance science.

QuidelOrtho's (QDEL) Rapid Antigen Test Gets CLIA Waiver

QuidelOrtho's (QDEL) receipt of the FDA's CLIA waiver is expected to widen access to the rapid antigen test in any point-of-care setting equipped with Sofia 2 instruments.

3 Reasons to Hold HealthEquity (HQY) Stock in Your Portfolio

HealthEquity's (HQY) strength in HSA raises optimism about the stock.

Abbott (ABT) Closes Acquisition Deal of Bigfoot Biomedical

Abbott's (ABT) footprint in the diabetes care market is increased by the Bigfoot Biomedical acquisition.

3 Reasons to Hold Veeva Systems (VEEV) Stock in Your Portfolio

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

Vasundhara Sawalka headshot

4 Stocks Trading Near 52-Week High That Can Climb Further

Investors target stocks that have been on a bullish run lately. Stocks like GIII, CEG, CWCO and DVA that are seeing price strength have a high chance of carrying the momentum forward.

McKesson (MCK) Announces Availability of FDA-Cleared Drug for MF

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for MF.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?

Here is how DaVita HealthCare (DVA) and McKesson (MCK) have performed compared to their sector so far this year.

Here's Why You Should Hold BD (BDX) Stock in Your Portfolio

BD's (BDX) slew of product launches raises optimism about the stock.

Inogen (INGN) Completes Buyout Deal to Expand Product Portfolio

Inogen's (INGN) latest acquisition is expected to expand its global Respiratory Care presence and potentially address a large growing bronchiectasis market.